NCT07404176 2026-02-11
TENET
Tata Memorial Hospital
Phase 2 Recruiting
Clinical Trials
12 trialsNCT07000162 2025-08-29
LART
Azienda USL Reggio Emilia - IRCCS
Phase 2 Recruiting
NCT05304546 2025-07-22
MK3475-C01
Sheba Medical Center
Phase 2 Completed
NCT06839144 2025-07-11
OC-POP-PT
Tel-Aviv Sourasky Medical Center
Phase 2 Recruiting
NCT02078700 2025-06-25
Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study.
Azienda USL Reggio Emilia - IRCCS
Phase 2 Completed
NCT04519151 2023-06-08
Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer
Sheba Medical Center
Phase 2 Recruiting
NCT04430361 2020-06-12
the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy
Henan Cancer Hospital
Phase 2 Unknown
NCT02747732 2019-04-23
Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL
Sheba Medical Center
Phase 2 Unknown
NCT03403777 2019-03-05
Avelumab in Refractory Testicular Germ Cell Cancer.
National Cancer Institute, Slovakia
Phase 2 Completed
NCT01472146 2017-05-09
ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer
Instituto Nacional de Cancer, Brazil
Phase 2 Completed
NCT01791387 2015-02-03
DILIGENCE-1
Auckland District Health Board
Phase 2 Unknown
NCT00411853 2009-07-31
Efficacy of FWGE in Combination With Hormone Therapy for the Treatment of Hormone-Refractory Prostate Cancer Patients
Sheba Medical Center
Phase 2 Unknown